Understanding the Role of Mineralocorticoid Receptor Antagonists and the Impact on Patient Care in Chronic Kidney Disease in Type 2 Diabetes

Gain expert insights on the evidence behind the use of finerenone in diabetic kidney disease selecting appropriate patients for finerenone therapy and strategies for overcoming clinical inertia.

Share

Program Content

Activities

MRAs in CKD in T2D
Understanding the Role of Mineralocorticoid Receptor Antagonists and the Impact on Patient Care in Chronic Kidney Disease in Type 2 Diabetes
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: April 29, 2022

Expires: April 28, 2023

View Activity

Activities

MRAs and the Impact on Patient Care in CKD in T2D
Understanding the Role of Mineralocorticoid Receptor Antagonists and the Impact on Patient Care in Chronic Kidney Disease in Type 2 Diabetes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 18, 2022

Expires: March 17, 2023

View Activity

Activities

Pearls on MRAs for T2D in CKD
Pearls on the Role of Mineralocorticoid Receptor Antagonists and the Impact on Patient Care in CKD in T2D
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: May 17, 2022

Expires: May 16, 2023

View Activity

Faculty

cover img faculity

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP

Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator

Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, Ohio

cover img faculity

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Vice Chair & Allen I. White Distinguished Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, Washington

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma